MAT / ABOUT / CANONICAL

2023 · Cambridge, MA

01 / ABOUT

Matilon

Matilon is a research boutique providing proprietary intelligence on biomanufacturing systems to select senior executives responsible for multi-year process architecture and industrialization decisions.

Inquiry

02 / OVERVIEW

Overview

Key figures

4 FIGURES

01Executives

700+

Senior executives

C-SUITE TO DIRECTOR

02Organizations

Organizations

ACROSS 2 SEGMENTS

03Spend

$50B+

Annual biomanufacturing spend

CAPEX · EQUIPMENT · OPS

04Coverage

80%+

Of major biopharma companies and CDMOs

MAJOR COMPANIES SERVED

03 / ORGANIZATIONS

Organizations

RELIED ON ACROSS BIOMANUFACTURING AND INDUSTRIALIZATION EXECUTIVE FUNCTIONS

24 OF 31 ORGANIZATIONS

Biopharma 21 · CDMOs 10

04 / FUNCTIONS SERVED

Functions Served

Functions served

5 FUNCTIONS

No.FunctionCoverageExample titles

Process Development and MSAT

Process design, scale-up, and manufacturing science for biologics and CGT programs, including technology transfer readiness, process control, and late-stage industrialization.

Coverage
Process development
MSAT
Tech transfer
Process engineering
Characterization

Example titles
Head of Process and Scale-Up Development
Programs Director, MSAT

Advanced Therapies Manufacturing

End-to-end CGT operations including cell processing, vector production, and platform integration, focused on closed-system reliability and GMP compliance.

Coverage
Cell therapy manufacturing
Gene therapy operations
ATMP engineering
Closed systems

Example titles
Director, Manufacturing Ops, Cell Therapy
VP CGT Operations

Tech Transfer and CMC Program Leadership

Technology transfer, comparability, and CMC program execution across sites, aligning development, quality, and regulatory teams for commercial readiness.

Coverage
Tech transfer
CMC strategy
Technical product leadership
Program readiness

Example titles
Head of CMC Program Management
Director, Technology Transfer Programs

Automation and Digital Manufacturing Systems

Automation, MES, and digital infrastructure deployment to standardize plant operations and data integrity.

Coverage
Digital manufacturing
Automation
Process control
MES
Manufacturing IT

Example titles
Director Manufacturing Systems
Head of Digital Manufacturing

Executive Manufacturing and TechOps

Long-term manufacturing and technology strategy, network expansion, and major capital program oversight.

Coverage
Technical operations
Manufacturing strategy
Capital deployment
Biomanufacturing roadmap

Example titles
VP, Drug Substance Manufacturing Networks
SVP Global Technical Operations

Seniority

3 LEVELS

Enterprise Leadership

Executives with authority over automation investment allocation, manufacturing network strategy, and enterprise-level supplier selection across biomanufacturing sites and organizational units.

Director, PD/Characterization

Vice President, Biologics MS&T

Program Leadership

Executives accountable for cross-site CGT, CMC, and manufacturing program ownership, including technology transfer coordination, supplier integration, and implementation across regional networks.

Head MSAT & Purification Technology

Global Head CMC Operations

Technical Leadership

Managers and technical specialists leading site-level execution within process, automation, and MSAT teams, overseeing deployment, validation, and performance optimization.

Lab Head Bioengineering Cell Therapy

CMC Project Lead Downstream Processing

05 / SERVICES

Services

SERVICE 01 / 03

Matilon Research

Open page

ISSUANCE · CONTROL REGISTRYBY REVIEW / INVITATION

Intelligence records issued on a fixed 7-day cadence, governing executive decisions on biomanufacturing process architecture and industrialization strategy.

ISSUANCE FREQUENCY: 7-DAY CYCLE
ISSUANCE CONTROL: FIXED RELEASE
DISTRIBUTION MODE: DIRECT, NON-PUBLIC DISTRIBUTION
ACCESS MODEL: ROLE-BOUND, NON-TRANSFERABLE
RETENTION MODEL: PERMANENT, APPEND-ONLY

ISSUANCE TIMELINE · 52 WEEKS2025-W44 – 2026-W44

Q4 2025

Q1 2026

12 ISSUED

Q2 2026

13 ISSUED

Q3 2026

14 ISSUED

DUE

SERVICE 02 / 03

Matilon Advisory

Open page

ENGAGEMENT PARAMETERS · FIELD REGISTRYBY REVIEW / INVITATION

Direct engagement with senior executives responsible for multi-year process architecture, manufacturing, and industrialization investment.

ENGAGEMENT FORM: BILATERAL, EXECUTIVE-LEVEL
SCOPE BASIS: CONSTITUTED PER ENGAGEMENT
DURATION: MULTI-MONTH TO MULTI-YEAR
CONFIDENTIALITY: NON-PUBLIC; NON-ATTRIBUTABLE
RECORD STATUS: ENGAGEMENT RECORD MAINTAINED

SERVICE 03 / 03

Matilon Events

Open page

CONVENING PARAMETERS · FIELD REGISTRYINVITATION ONLY

Private, invite-only convenings designated for biologics and CGT manufacturing executives across industrialization programs.

CONVENING FORM: PRIVATE, INVITE-ONLY ROUNDTABLE
PARTICIPATION: SENIOR BIOLOGICS / CGT MANUFACTURING EXECUTIVES
CONFIDENTIALITY: CHATHAM HOUSE RULE; NON-PUBLIC
CONVENING BASIS: INVITATION ONLY; CONSTITUTED AT MATILON DISCRETION
RECORD STATUS: INTERNAL CONVENING RECORD MAINTAINED

06 / SEGMENTS

Segments

SEGMENT 01 / 02

BIOPHARMA · 21 ORGANIZATIONS

Biopharma

Open page

ADDRESSED DECISIONS3 DECISIONS

Process architecture standardized across mAbs, CGT, and ADC programs and global manufacturing scales.

01STANDARDIZE PROCESS ARCHITECTURE ACROSS MODALITIES
02BALANCE INTERNAL PRODUCTION AND CDMO USE
03MANAGE TECH TRANSFER AND SCALE-UP

ORGANIZATIONSBIOPHARMA

SEGMENT 02 / 02

CDMO · 10 ORGANIZATIONS

CDMOs

Open page

ADDRESSED DECISIONS3 DECISIONS

Manufacturing systems aligned to sponsor platforms and balanced across multi-client programs.

01ALIGN TO SPONSOR PROCESS PLATFORMS
02ALLOCATE CAPACITY ACROSS CLIENT PROGRAMS
03BALANCE STANDARDIZATION AND SPONSOR CUSTOMIZATION

ORGANIZATIONSCDMO

07 / RECORDS

Records

DOCUMENT 01 / 04

Record Index

Open page

RECORD INDEXLAST 52 ISSUANCES · 1 SCHEDULED

Canonical index of issued records, retained permanently under append-only governance and chained sequence.

Record IDWeekIssuedSchemaEntriesAccessStatus

MT-2026-10-28-V12026-W442026-10-283.24–8EXECUTIVESCHEDULED

MT-2026-10-21-V12026-W432026-10-213.24–8EXECUTIVEFINALIZED

MT-2026-10-14-V12026-W422026-10-143.24–8EXECUTIVEFINALIZED

MT-2026-10-07-V12026-W412026-10-073.24–8EXECUTIVEFINALIZED

DOCUMENT 02 / 04

Record Specimen

Open page

MT-2026-02-18-V1.pdfapplication/pdf · PDF/A-2b

Complete specimen issuance rendered across the issued record, HTML, and structured-text representations.

DOCUMENT 03 / 04

Schema Reference

Open page

RECORD CONTROL · FIELD REGISTRYSCHEMA v3.2 · 12 FIELDS

Reference for record control, registers, entry structure, and field anchors administered under the current schema.

RECORD_CONTROL

TYPE: Record class, as declared by the record

RECORD_ID: PREFIX-YYYY-MM-DD-Vn

PRECEDING_RECORD: Chained reference to prior record; — where the record opens a series

RECORD_SIGNATURE: UUID, generated at issuance (RFC 4122)

VERSION: MAJOR.MINOR; MINOR RESERVED FOR CORRECTIONS

STATUS: DRAFT | FINALIZED | SUPERSEDED

ISSUED: ISO-8601 DATE

RECORD_MODE: APPEND-ONLY AFTER FINALIZATION

RETENTION_PERIOD: PERMANENT

SCHEMA_VERSION: REFERENCE TO GOVERNING SCHEMA

ACCESS_CLASSIFICATION: EXECUTIVE | RESTRICTED | INTERNAL

ENTRY_COUNT: Count of entries contained in the record

DOCUMENT 04 / 04

Extraction Specification

Open page

EXTRACTION PASSMT-2026-02-18-V1 · SCHEMA v3.2

Published specification governing record extraction, conformance markers, and classification.

record.type = "INTELLIGENCE"

record.record_id = "MT-2026-02-18-V1"

record.preceding_record = "MT-2026-02-11-V1"

record.record_signature = "7A2E9C4F-3B81-4D56-A9E3-2F7C8B1D5E04"

record.version = "1.0"

record.status = "FINALIZED"

record.issued = "2026-02-18"

record.record_mode = "APPEND-ONLY"

record.retention_period = "PERMANENT"

record.schema_version = "3.2"

record.access_classification = "EXECUTIVE"

record.entry_count = 5

record.entry[0].entry_id = "MT-2026-02-18-V1-E1"

record.entry[0].ingestion_id = "3C9F1A47-5D8B-4E62-B1F4-8A2E6C5D3B19"

record.entry[0].entity = ["FUJIFILM BIOTECHNOLOGIES"]

record.entry[0].subject = "TEESSIDE SINGLE-USE BIOREACTOR CAPACITY EXPANSION"

record.entry[0].subject_class = "EXPANSION"

record.entry[0].domain = "BIOMANUFACTURING CAPACITY"

record.entry[0].geography = ["UNITED KINGDOM"]

record.entry[0].functional_domain = ["PROCESS DEVELOPMENT AND MSAT", "TECH TRANSFER AND CMC PROGRAM LEADERSHIP", "EXECUTIVE MANUFACTURING AND TECHOPS"]

record.entry[0].body.definition = "FUJIFILM Biotechnologies opened a £400 million Teesside expansion, adding 2,000 L and 5,000 L single-use bioreactors alongside new process development laboratories."

record.entry[0].body.structure = "End-to-end workflows now run from customer-supplied DNA through cell line development to 5,000 L scale-up, reducing external handoffs during tech transfer."

record.entry[0].body.effect = "Raises the value of standardized process definitions, facility layouts, and shared digital templates as Teesside aligns with FUJIFILM's Toyama facility."

record.entry[1].entry_id = "MT-2026-02-18-V1-E2"

record.entry[1].ingestion_id = "8E4A2F91-6C3D-4B57-9A2E-1F5C8D7B4A63"

record.entry[1].entity = ["MADE SCIENTIFIC", "STREAMLINE BIO"]

08 / CAREERS

Careers

Matilon hires senior specialists across research, advisory, events and operations. Open positions are listed on the careers page.

Careers0 OPEN POSITIONS

09 / ACCESS

Access

Access to Matilon Research, Matilon Advisory and Matilon Events is by review or invitation. Inquiries are evaluated on relevance, scope, and program stage.

Inquiry